AbbVie Inc. (NYSE: ABBV) dipped 0.6% to $67.34, after Express Scripts Holding Co., the largest manager of U.S. prescription-drug benefits, decided an AbbVie drug will be its exclusive option for treating the most common form of hepatitis C. Share volume was 675,000, compared to an all-day average of 2.3 million
